Recombinant human pd l1 fc chimera protein

Manufactured by R&D Systems

Recombinant human PD-L1–Fc chimera protein is a laboratory reagent produced by R&D Systems. It consists of the extracellular domain of human PD-L1 fused to the Fc region of human IgG1. This protein is commonly used in research applications to study the structure, function, and interactions of the PD-L1 protein.

Automatically generated - may contain errors

Lab products found in correlation

Atezolizumab, by Roche (2 mentions) Donkey anti human igg hrp, by Jackson ImmunoResearch (2 mentions) Durvalumab, by AstraZeneca (2 mentions) Anti human alexa fluor 488 dye conjugate, by Thermo Fisher Scientific (1 mentions) Incucyte live cell analysis system, by Sartorius (1 mentions) Imfinzi, by AstraZeneca (1 mentions)

4 protocols using recombinant human pd l1 fc chimera protein

Isolating and Staining Human PBMCs

Check if the same lab product or an alternative is used in the 5 most similar protocols

PBMCs were obtained from human blood by centrifugation in a gradient of Percoll (PromoCell). Cells were collected and stained as described in Flow cytometry and cell sorting. To stain for apoptosis, human lymphocytes were cultured with 5 μg/mL recombinant human PD-L1–Fc chimera protein (R&D Systems, 156-B7) overnight.

Becker-Gotot J., Meissner M., Kotov V., Jurado-Mestre B., Maione A., Pannek A., Albert T., Flores C., Schildberg F.A., Gleeson P.A., Reipert B.M., Oldenburg J, & Kurts C. (2022). Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs. The Journal of Clinical Investigation, 132(22), e159925.

+ Open protocol

+ Expand

Quantifying PD-1/PD-L1 Binding Kinetics

Check if the same lab product or an alternative is used in the 5 most similar protocols

To measure PD-1/PD-L1 interaction, PD-1- expressing 293T cells were incubated with recombinant human PD-L1-Fc chimera protein (R&D Systems) for 1 hour and then anti-human Alexa Fluor 488 dye conjugate (Life Technologies). The fluorescence intensity of Alexa Fluor 488 dye was then monitored using a real-time IncuCyte live-cell analysis system (Essen BioScience, Ann Arbor, ML, USA) according to the manufacturer’s instructions.

Sun L., Li C.W., Chung E.M., Yang R., Kim Y.S., Park A.H., Lai Y.J., Yang Y., Wang Y.H., Liu J., Qiu Y., Khoo K.H., Yao J., Hsu J.L., Cha J.H., Chan L.C., Hsu J.M., Lee H.H., Yoo S.S, & Hung M.C. (2020). Targeting glycosylated PD-1 induces potent anti-tumor immunity. Cancer research, 80(11), 2298-2310.

+ Open protocol

+ Expand

Characterization of Recombinant PD-L1 Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human recombinant PD-L1 (Phe19-Thr239) with C-terminal 6xHis tag produced in HEK293 cells and human recombinant PD-L1-Fc chimera protein produced in mouse NS0 cells were obtained from R&D Systems, Minneapolis, MN (cat # 9049-B7 and 156-B7, respectively). Human PNGase F for N-deglycosylation was obtained from New England Biolabs, Ipswitch, MA (cat # B3704). Anti-human PD-L1 antibodies, Durvalumab (Imfinzi, Astra Zeneca), Avelumab (Bavencio, EMD Serona), and Atezolizumab (Tecentriq, Roche) were obtained from Oncology Pharmacy, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC as discarded reagents from ongoing clinical studies. Donkey anti-human IgG- HRP was from Jackson ImmunoResearch (cat # 709-035-149).

Benicky J., Sanda M., Kennedy Z.B., Grant O.C., Woods R.J., Zwart A, & Goldman R. (2020). PD-L1 glycosylation and its impact on binding to clinical antibodies. Journal of proteome research, 20(1), 485-497.

+ Open protocol

+ Expand

Recombinant PD-L1 Protein Production

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human recombinant PD-L1 (Phe19-Thr239) with C-terminal 6xHis tag produced in HEK293 cells and human recombinant PD-L1-Fc chimera protein produced in mouse NS0 cells were obtained from R&D Systems, Minneapolis, MN (cat # 9049-B7 and 156-B7, respectively). Human PNGase F for Ndeglycosylation was obtained from New England Biolabs, Ipswitch, MA (cat # B3704). Anti-human PD-L1 antibodies, Durvalumab (Imfinzi, Astra Zeneca), Avelumab (Bavencio, EMD Serona), and Atezolizumab (Tecentriq, Roche) were obtained from Oncology Pharmacy, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC as discarded reagents from ongoing clinical studies. Donkey anti-human IgG-HRP was from Jackson ImmunoResearch (cat # 709-035-149).

Benický J., Šanda M., Kennedy Z.B., Grant O.C., Woods R.J., Zwart A., & Goldman R. (2020). PD-L1 glycosylation and its impact on binding to clinical antibodies.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!